RU2449996C2 - СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ - Google Patents

СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ Download PDF

Info

Publication number
RU2449996C2
RU2449996C2 RU2009121808/04A RU2009121808A RU2449996C2 RU 2449996 C2 RU2449996 C2 RU 2449996C2 RU 2009121808/04 A RU2009121808/04 A RU 2009121808/04A RU 2009121808 A RU2009121808 A RU 2009121808A RU 2449996 C2 RU2449996 C2 RU 2449996C2
Authority
RU
Russia
Prior art keywords
cancer
bcl
compound
carcinoma
compounds
Prior art date
Application number
RU2009121808/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2009121808A (ru
Inventor
Альфредо С. КАСТРО (US)
Альфредо С. КАСТРО
Эдуард Б. ХОЛСОН (US)
Эдуард Б. ХОЛСОН
Брайан Т. ХОПКИНС (US)
Брайан Т. ХОПКИНС
Най О. КОУНИ (US)
Най О. КОУНИ
Даниел А. СНАЙДЕР (US)
Даниел А. СНАЙДЕР
Томас Т. ТИББИТТС (US)
Томас Т. ТИББИТТС
Original Assignee
Инфинити Дискавери, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инфинити Дискавери, Инк. filed Critical Инфинити Дискавери, Инк.
Publication of RU2009121808A publication Critical patent/RU2009121808A/ru
Application granted granted Critical
Publication of RU2449996C2 publication Critical patent/RU2449996C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2009121808/04A 2006-11-15 2007-11-14 СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ RU2449996C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US11/600,332 2006-11-15

Publications (2)

Publication Number Publication Date
RU2009121808A RU2009121808A (ru) 2010-12-20
RU2449996C2 true RU2449996C2 (ru) 2012-05-10

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009121808/04A RU2449996C2 (ru) 2006-11-15 2007-11-14 СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ

Country Status (20)

Country Link
US (2) US7842815B2 (enExample)
EP (1) EP2094673B1 (enExample)
JP (2) JP2010510214A (enExample)
KR (1) KR101530721B1 (enExample)
CN (1) CN101583606B (enExample)
AU (1) AU2007319848B2 (enExample)
BR (1) BRPI0718606A2 (enExample)
CA (1) CA2669596C (enExample)
EC (1) ECSP099398A (enExample)
ES (1) ES2537762T3 (enExample)
GT (1) GT200900123A (enExample)
IL (1) IL198597A (enExample)
MA (1) MA31067B1 (enExample)
MX (1) MX2009005184A (enExample)
MY (1) MY156754A (enExample)
NO (1) NO20092306L (enExample)
NZ (1) NZ577243A (enExample)
RU (1) RU2449996C2 (enExample)
TN (1) TN2009000182A1 (enExample)
WO (1) WO2008060569A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
CN104474529A (zh) * 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
JP6141327B2 (ja) 2012-02-06 2017-06-07 ディスカヴァーエックス コーポレイション タンパク質存在量の測定による細胞内結合事象の検出
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
ES2774932T3 (es) 2012-11-14 2020-07-23 Cj Cheiljedang Corp Producción de sales de 4-hidroxibutirato utilizando materias primas de base biológica
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
BR112016017564A8 (pt) 2014-01-28 2018-04-17 Buck Inst Res Aging métodos e composições para matar células senescentes e para tratar doenças e transtornos associados à senescência
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
RU2726367C2 (ru) 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
IL288991B2 (en) * 2017-04-05 2023-12-01 Harvard College Macrocyclic compound and uses thereof
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
WO2022008464A1 (en) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145961C1 (ru) * 1993-05-01 2000-02-27 Мерк Патент Гмбх Оксазолидиноны, их соли, способ их получения, фармацевтический препарат и способ его получения

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
JP2995086B2 (ja) 1990-05-18 1999-12-27 ヘキスト・アクチエンゲゼルシヤフト イソオキサゾール−４−カルボキサミド類およびヒドロキシアルキリデンシアノアセトアミド類を含有する製剤
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0730590B1 (en) 1993-11-24 2001-01-17 Dupont Pharmaceuticals Company isoxazoline and isoxazole fibrinogen receptor antagonists
EP0749428B1 (en) 1994-03-09 1998-07-29 Pfizer Inc. Isoxazoline compounds as inhibitors of tnf release
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
AU4064597A (en) 1996-08-16 1998-03-06 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
ES2387211T3 (es) 1997-05-07 2012-09-18 University Of Pittsburgh Inhibidores de proteínas isoprenil transferass
WO2001016115A1 (en) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
US20030008924A1 (en) 2001-05-30 2003-01-09 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
US20060020004A1 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
JP5064213B2 (ja) 2004-06-17 2012-10-31 インフィニティ・ディスカバリー・インコーポレイテッド Ｂｃｌタンパク質と結合パートナーとの相互作用を阻害する化合物および方法
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145961C1 (ru) * 1993-05-01 2000-02-27 Мерк Патент Гмбх Оксазолидиноны, их соли, способ их получения, фармацевтический препарат и способ его получения

Also Published As

Publication number Publication date
US20110160259A1 (en) 2011-06-30
CN101583606B (zh) 2015-04-08
NO20092306L (no) 2009-08-17
WO2008060569A1 (en) 2008-05-22
TN2009000182A1 (en) 2010-10-18
IL198597A (en) 2014-03-31
KR101530721B1 (ko) 2015-06-22
AU2007319848B2 (en) 2012-05-03
ECSP099398A (es) 2009-07-31
GT200900123A (es) 2011-09-02
KR20090082284A (ko) 2009-07-29
ES2537762T3 (es) 2015-06-11
US20070161690A1 (en) 2007-07-12
EP2094673B1 (en) 2015-04-08
US7842815B2 (en) 2010-11-30
US8461191B2 (en) 2013-06-11
JP2010510214A (ja) 2010-04-02
CA2669596A1 (en) 2008-05-22
MA31067B1 (fr) 2010-01-04
RU2009121808A (ru) 2010-12-20
CN101583606A (zh) 2009-11-18
AU2007319848A1 (en) 2008-05-22
BRPI0718606A2 (pt) 2013-12-17
JP2014055156A (ja) 2014-03-27
HK1130057A1 (en) 2009-12-18
CA2669596C (en) 2014-09-30
MX2009005184A (es) 2009-10-12
NZ577243A (en) 2011-12-22
EP2094673A1 (en) 2009-09-02
IL198597A0 (en) 2010-02-17
US20080306127A9 (en) 2008-12-11
MY156754A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
RU2449996C2 (ru) СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ
RU2416606C2 (ru) Соединения и способы для ингибирования взаимодействия bcl белков с компонентами по связыванию
CN104487429B (zh) 杂环黄酮衍生物、组合物及与其相关的方法
CN108463224A (zh) sGC刺激剂用于胃肠功能障碍治疗的应用
TW201940487A (zh) sGC刺激劑之晶型
US20020160991A1 (en) Orally-bioavailable formulations of fentanyl and congeners thereof
CN102046163A (zh) 使用乌地那非(udenafil)与阿呋唑嗪(alfuzosin)或奥昔布宁(oxybutynin)组合治疗膀胱过度活动症
HK1130057B (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161115